| Document |
Document Title |
|
WO/2023/180162A1 |
The present invention relates to a new method for producing compounds of formula (II) by reacting compounds of formula (I) with hydrogen peroxide in the presence of a solvent, in the presence of a catalyst, in the presence of a buffer an...
|
|
WO/2023/179071A1 |
A method for preparing a high-purity fluorination derivative of ethylene carbonate. The method comprising: using chloroethylene carbonate or 4,5-dichloroethylene carbonate as a raw material and a fluoride as a fluorinating agent, subject...
|
|
WO/2023/182378A1 |
The present invention provides: a polycarbonate resin that includes a structural unit represented by formula (1) (in which A is an optionally substituted trivalent alicyclic moiety, and B is an optionally substituted monovalent alicyclic...
|
|
WO/2023/182309A1 |
This compound is represented by formula (1). (In formula (1), R1 represents a hydrogen atom, a methyl group, an ethyl group, a methacryloyloxymethyl group, or an acryloyloxymethyl group. R2 represents a hydrogen atom or a methyl group. R...
|
|
WO/2023/182772A1 |
The present invention relates to a synthesis method for alkylene carbonate, for example, alkylene carbonate comprising propylene carbonate, ethylene carbonate, and the like and, more specifically to, a synthesis method for alkylene carbo...
|
|
WO/2023/182771A1 |
The present invention relates to a method for synthesizing alkylene carbonate, that is, alkylene carbonate including ethylene carbonate and propylene carbonate, and, more specifically, to a method for electrochemically synthesizing alkyl...
|
|
WO/2023/177590A1 |
A method for direct synthesis of cyclic carbonates is achieved by reacting at least one epoxide with carbon dioxide in the presence of a choline catalyst, such as choline chloride, under mild conditions such as a temperature between abou...
|
|
WO/2023/177877A1 |
Described herein are ralinepag prodrugs, as well as pharmaceutical compositions thereof, and methods of use thereof in the treatment of diseases or conditions that would benefit from treatment with a prostacyclin (IP) receptor agonist co...
|
|
WO/2023/166004A1 |
The present invention relates to the field of organic synthesis and more specifically it concerns a process for preparing compound of formula (I). The compound of formula (III), the compound of formula (IV) and the compound of formula (V...
|
|
WO/2023/166005A1 |
The present invention relates to the field of organic synthesis and more specifically it concerns a process for preparing compound of formula (I) from a compound of formula (II). The process to prepare compound of formula (II) and the co...
|
|
WO/2023/160035A1 |
A β-elemene vinylation coupled derivative, and a preparation method therefor and the use thereof in the preparation of an antitumor drug. Provided are a β-elemene vinylation coupled derivative having a structure as represented by formu...
|
|
WO/2023/160011A1 |
Disclosed are a β‑Elemene derivative containing an N-OH bond, a preparation method therefor and a use thereof. The present invention provides a class of β‑Elemene derivatives containing an N-OH bond having the structure shown in fo...
|
|
WO/2023/160672A1 |
The present disclosure provides LPA antagonists of formula I, as well as pharmaceutical compositions comprising the compounds disclosed herein. Also provided are methods for treating LPA-associated diseases, disorders, and conditions.
|
|
WO/2023/164544A2 |
Provided herein, inter alia, novel ionizable cationic lipids, lipid nanoparticles comprising the novel ionizable cationic lipids and methods of using said nanoparticles.
|
|
WO/2023/158584A1 |
The invention provides new bicyclopentanyl compounds having the general formula (I), or a solvate or a pharmaceutically acceptable salt thereof: wherein R1, R2, R3, R4, and R5 are as defined herein, compositions including the compounds, ...
|
|
WO/2023/156453A1 |
There are disclosed psychedelic and entactogen compounds, the use of such compounds in the treatment of diseases associated with a serotonin receptor or monoamine transporter, pharmaceutical compositions such as tablet compositions and k...
|
|
WO/2023/152691A1 |
The present invention relates to a process for the preparation of Ponesimod of formula I and its intermediates thereof.
|
|
WO/2023/153296A1 |
Provided are a radiation-sensitive resin composition capable of forming a resist film with excellent sensitivity, LWR performance, water repellency, and suppression of development flaws, and having good storage stability; and a pattern f...
|
|
WO/2023/153294A1 |
The purpose of the present invention is to provide: a radiation-sensitive resin composition which enables the formation of a resist film having excellent sensitivity, LWR performance, water repellency and development defect reducing prop...
|
|
WO/2023/149432A1 |
The objective of the present disclosure is to provide a composition with a stabilized fluorine-containing monomer, a method for stabilizing a fluorine-containing monomer, etc. The present disclosure relates to the following composition...
|
|
WO/2023/143988A1 |
The present invention relates to a compound of formula (I) wherein X is selected from the group consisting of oxo, sulfanyl and hydroxy, and if X is hydroxy, the stereocenter in position (3) is in S configuration; R1 is selected from the...
|
|
WO/2023/143455A1 |
The present application relates to a 3-[(benzo[d][1,3]dioxolane-4-yl)oxy]propylamine hydrochloride, a crystalline form thereof, and a preparation method therefor. A crystal form A of an (R)-N-methyl-3-phenyl-3-[(benzo[d][1,3]dioxolane-4-...
|
|
WO/2023/144370A1 |
The current invention relates to an agrochemical composition comprising at least one agrochemical active component and a solvent. Furthermore, the present invention also relates to a method for applying aforementioned agrochemical compos...
|
|
WO/2023/139163A1 |
Disclosed herein are novel 1,3-benzodioxole esters and their homologues, having various advantages over current compounds used in certain methods of drug-assisted therapy, such as MDMA, together with pharmaceutical compositions containin...
|
|
WO/2023/138074A1 |
The present invention provides a method and system for preparing a cyclic carbonate by catalyzing carbon dioxide cycloaddition. The method comprises the following steps: carrying out a cycloaddition reaction by using a Schiff base metal ...
|
|
WO/2023/137453A1 |
The present disclosure relates to compounds Formula (I): methods for making the compounds and methods for their use.
|
|
WO/2023/134191A1 |
The present invention relates to the technical field of lithium battery electrolyte additives, and particularly discloses a method for purifying vinylene carbonate by coupled rectification-melt crystallization technology. The method comp...
|
|
WO/2023/137446A1 |
The present disclosure relates to prodrugs of 3,4-methylenedioxy-N-ethyl-amphetamine (MDEA), methods for making the prodrugs and the methods for their use in treating brain and neurological disorders.
|
|
WO/2023/129958A2 |
Provided herein are compounds of Formula (I), Formula (II), and Formula (III) or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7 and A are defined herein. Also provided herein are pharmaceutical compositions ...
|
|
WO/2023/127808A1 |
There is still a great amount of damage by pests or the like in production of agricultural crops, horticultural crops, and the like, and the development of novel pest control agents is desired due to factors such as the emergence of pest...
|
|
WO/2023/127807A1 |
In the production of agricultural and horticultural crops, etc., damages caused by pest insects, etc. are still significant, and, therefore, the development of novel pest control agents has been required due to factors such as the emerge...
|
|
WO/2023/120250A1 |
Provided is an actinic-ray-sensitive or radiation-sensitive resin composition, etc. that, when forming an ultra-fine pattern (for example, a line and space pattern of 25 nm or less, or a hole pattern with a hole diameter of 25 nm or less...
|
|
WO/2023/117119A1 |
The present invention relates to the field of flavors and more specifically to new representatives of this group, in particular active ingredients having a sialagogue effect. The invention also relates to the use of these active ingredie...
|
|
WO/2023/115002A1 |
The present disclosure relates to compound Formula (I) methods for making the compounds and methods for their use.
|
|
WO/2023/114822A1 |
The disclosure relates to compounds of Formula (I), which are RXFP1 receptor agonists, compositions containing them, and methods of using them, for example, in the treatment of heart failure, fibrotic diseases, and related diseases such ...
|
|
WO/2023/107877A1 |
Glycerol acetal sulfate and sulfonates, which may be used in consumer products to provide surfactant properties.
|
|
WO/2023/103137A1 |
An orthoester mixture pharmaceutical excipient, relating to the field of pharmaceutical excipients, and mainly obtained by mixing different orthoester compounds in different proportions or by mixing orthoester compounds with biocompatibl...
|
|
WO/2023/107715A1 |
The present invention discloses specialized combinations and methods of use thereof that may be used for beneficially modulating the central nervous system and for treating central nervous system, inflammatory, and metabolic disorders.
|
|
WO/2023/098189A1 |
The present invention relates to the technical field of lithium battery additives. Disclosed are a preparation process for fluoroethylene carbonate and a lithium battery applying fluoroethylene carbonate. The preparation process comprise...
|
|
WO/2023/098188A1 |
The present application relates to the technical field of lithium batteries, and specifically discloses a preparation method for vinylene carbonate, and a lithium battery electrolyte using vinylene carbonate. The purity of vinylene carbo...
|
|
WO/2023/094830A1 |
Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof wherein Ring A, Ring B, R1, R2, R3 and L are as defined herein. The compounds are antagonists of the resistant (R-type) voltage-gated calcium ion ch...
|
|
WO/2023/092195A1 |
Analogues of 3,4-methylenedioxymethamphetamine (MDMA), processes for their preparation, medicaments and medical methods of treatment comprising said MDMA analogues, and medical uses of said MDMA analogues. The MDMA analogues are capable ...
|
|
WO/2023/092175A1 |
The invention relates generally to a compound of Formula (I), wherein R1 is a bicyclic fused heterocyclic moiety and R2 is H or F. The compound of Formula (I) or a pharmaceutically acceptable salt thereof has potential medical use in the...
|
|
WO/2023/092044A2 |
Disclosed herein are salts and solid forms of MDMA, (R)-MDMA, (S)-MDMA, MDE, MDAI, MBDB, MEAI, and 5,6-Dimethoxy-2-aminoindane, including salts, solid forms of the compound and salts thereof, as well as polymorphs of solid forms. The sol...
|
|
WO/2023/081895A1 |
Disclosed herein are isotopically enriched compounds and methods of using both isotopically and non-isotopically enriched compounds of the following formula (I), in the treatment of neurologic and brain disorders/conditions.
|
|
WO/2023/078824A1 |
The present invention relates to compounds of the spiro-(indane- fluorene) type of formula (I), in particular those bearing a primary amino group and the corresponding diarylamino compounds. The invention further relates to methods for p...
|
|
WO/2023/081403A1 |
Described herein are isotopically enriched analogs of methylone (e.g., deuterated analogs of methylone (e.g., (S)-methylone and (R)-methylone) with improved characteristics. Also described herein are salts (such as hydrochloride salt) an...
|
|
WO/2023/078909A1 |
The present invention relates to compounds of formula (I), a delivery system based on photoresponsive cyclic acetal or ketal compounds capable of liberating in a controlled manner active volatile carbonyl compounds into the surrounding u...
|
|
WO/2023/081899A1 |
Disclosed herein are isotopically enriched compounds and methods of using both isotopically and non-isotopically enriched compounds of the following formula (I) in the treatment of neurologic and brain disorders/conditions.
|
|
WO/2023/081753A1 |
The present invention provides R-3,4-methylenedioxy-N,N-dimethylamphetamine, and salts thereof, for treating brain disorders.
|
